Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated, single-arm, single-center, prospective clinical study with
an estimated 58 patients enrolled to explore the efficacy and safety of anrotinib
hydrochloride in combination with doxorubicin and radiotherapy in patients with high-grade
soft tissue sarcoma.